BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology’s DPX-based vaccines have shown impressive efficacy in combating various infectious diseases, with a single dose providing 100% immunity in certain studies. The company’s DPX platform has generated strong and lasting immune responses and is being considered for further development and partnerships, including off-balance sheet financing options.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
